Human Genome Sciences And Transgene Sign Gene Therapy Drug Deal | GenomeWeb

ROCKVILLE, Md.--Human Genome Sciences here and French biotechnology company Transgene announced in early March a 10-year agreement to accelerate the development of novel gene therapy drugs. HGS will combine its genomics database with Transgene's broad technology platform of gene delivery systems, the companies said.

Transgene will have rights to exclusively license and sublicense up to 10 genes and to develop, manufacture, and commercialize any resulting gene therapy products worldwide.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.